Key takeaway: Sun Pharmaceutical Industries Limited reported its Q1 FY27 earnings, highlighting a sales increase of 10.1% year-over-year, reaching INR 151,836 million. The gross margin improved to 80.5%, attributed to a better product mix. EBITDA rose by 2.7% to INR 44,177 million, with EBITDA margins at 28.9%. The net profit after tax was INR 28,948 million, with an adjusted net profit of INR 30,894 million. The company noted a lower forex gain of INR 1,220 million compared to the previous year. In the U.S. market, sales declined by 9.7% to USD 427 million, primarily due to lower generic sales and increased competition. The India business saw a 16% growth, driven by strong performance in innovative medicines and new product launches. Management also discussed the ongoing acquisition of Organon, which is on track to close by early 2027, and emphasized the importance of their R&D investments, which accounted for 5.4% of sales in the quarter.

Key takeaway: Sun Pharmaceutical Industries Limited's investor presentation, dated July 7, 2026, outlines the company's performance and strategic focus. The presentation highlights that Sun Pharma operates in over 100 countries and is a leading global specialty generic company. For FY26, the company reported sales of Rs 582 billion, with a diversified revenue base comprising 33% from India, 29% from the US, and 19% from emerging markets. Management noted a strong EBITDA margin of 30.3% and emphasized a commitment to R&D, investing 6.1% of sales. The company aims to enhance its innovative medicines portfolio, which accounted for 22% of sales in FY26, and continues to focus on sustainability and corporate governance. The presentation also detailed recent acquisitions and strategic partnerships to bolster its market position.

Key takeaway: Sun Pharmaceutical Industries Limited reported its Q4 FY26 earnings during the conference call held on May 22, 2026. Management highlighted a sales increase of 13.6% year-over-year, reaching INR 145,598 million, with a gross margin of 80.8%. EBITDA for the quarter was INR 39,542 million, reflecting a 6.4% increase, while the EBITDA margin decreased to 27.1%. The net profit after tax was reported at INR 27,140 million. For the full year FY26, sales grew by 11.9% to INR 582 billion, with an adjusted net profit of INR 124,015 million. Management announced a final dividend of INR 5 per share, complementing the interim dividend of INR 11 per share. The call also covered updates on the acquisition of Organon & Company and the performance of various business segments, including Innovative Medicines and the U.S. market. Management set a goal of high single-digit consolidated top line growth for FY27 and indicated an R&D spend of 6% to 7% of sales for the next year.

Key takeaway: Sun Pharmaceutical Industries Limited held an investor call on April 27, 2026, to discuss its acquisition of Organon & Company. Management, including Chairman Dilip Shanghvi and Managing Director Kirti Ganorkar, expressed excitement about the strategic nature of the acquisition, highlighting the potential for growth despite Organon's current stagnation. Shanghvi noted that the acquisition would involve taking on significant debt, but emphasized the manageable debt-to-EBITDA ratio of 2.3 times. Ganorkar detailed Organon's strong brand equity and global presence, particularly in women's health, and outlined plans to leverage synergies between the two companies. The management projected that the combined entity would generate substantial free cash flow and highlighted the importance of integrating both companies' cultures and operational strengths. The call concluded with a Q&A session addressing various aspects of the acquisition and future growth strategies.

Key takeaway: The investor presentation from Sun Pharmaceutical Industries Limited, dated February 24, 2026, outlines the company's global operations, financial performance, and strategic focus areas. Sun Pharma operates in over 100 countries, with a diversified business model that includes innovative medicines, branded generics, and active pharmaceutical ingredients (APIs). The presentation highlights a strong revenue composition, with 33% from India formulations and 31% from US formulations, totaling Rs 520 billion in FY25 sales. Management reported a compound annual growth rate (CAGR) of 19% in sales from FY10 to FY25. The company emphasized its commitment to sustainability, with significant investments in R&D, accounting for 6.2% of sales. Sun Pharma also detailed its corporate governance structure, with a balanced board composition. The presentation concluded with a focus on enhancing innovative product offerings and maintaining leadership in key markets.

Key takeaway: During the Q3 FY26 earnings call, Sun Pharmaceutical Industries Limited reported consolidated sales of Rs. 154,691 million, reflecting a growth of 15.1% compared to Q3 FY25. The company achieved a gross margin of 81%, attributed to an improved product mix. EBITDA for the quarter was Rs. 49,485 million, marking a 23.4% increase year-on-year, with an EBITDA margin of 31.9%. The net profit after tax was Rs. 33,688 million, up 16% from the previous year. The company declared an interim dividend of Rs. 11 per share. Management highlighted strong performance in the India market, with sales formulations growing by 16.2%. The US business saw a slight increase of 0.6% in sales, impacted by competition in the generic segment. Management also discussed ongoing R&D investments and the launch of new products, including Unloxcyt and Ilumya, while addressing speculation regarding M&A activities.